445680 KR · Curiox BiosystemsMW GOBLIN RESEARCH
Curiox: Growth Expectations Outpace Progress in Orders
Analysis date
Published
As of 2026-10-18, commercialization progress is positive, but the valuation burden at KRW 68,100 is substantial. Confirmation is needed that orders for multiple instruments lead to repeat purchases and reduce operating losses.
Read the reasoning behind the analysis
The full report includes key metrics, detailed analysis, valuation, and sources.
Read up to three full reports daily without signing in.
Read the full reportWhat this report covers
- From Orders for Multiple Instruments to Repeat Purchases
- The Dual Burden of Operating Cash Outflows and Bond Repurchases